91°µÍø

Professor Ludovic Pelligand

DocMedVet CertVA DipECVAA, DipECVPT PhD MRCVS
Professor in Clinical Pharmacology and Anaesthesia

Department: Clinical Science and Services

Campus: Hawkshead

Research Groups: Food Safety, Antimicrobial Resistance, IRLFS (Research Programme), Cardiovascular and Renal Biology, Brain Health and Behaviour, CPCS (Research Programme)

Clinical Groups: Small Animal Anaesthesia, Large Animal Anaesthesia

Research Centres: 91°µÍø Quantitative Biology Resource, Clinical Investigation Centre

Ludovic is a diplomate of the ECVAA and ECVPT. He is currently Professor in Veterinary Clinical Pharmacology and Anaesthesia. He is co-head of the 91°µÍø anaesthesia service. Ludovic has a passion for clinically applied research in the field of inflammation and pain and in the field of veterinary antimicrobial drugs.

Ludovic graduated from the École Nationale Vétérinaire d'Alfort (Paris, France) in 2001, where he completed a two-year small animal internal medicine internship. He then completed a 3-year anaesthesia residency at the 91°µÍø (91°µÍø), London, UK where he gained his European Diploma of Veterinary Anaesthesia and Anaesthesia in 2006.

Ludovic completed his pharmacology PhD at the 91°µÍø in 2010 on the roles of cyclooxygenase (COX) isoenzymes in the regulation of inflammation and the renal function in the cat (supervised by Professor Jonathan Elliott and Professor Peter Lees and Dr. Jon King).

Ludovic has been back in the clinics as a senior anesthetist since the end of his PhD. He is currently Professor in Veterinary Clinical Pharmacology and Anaesthesia.

Ludovic gained the European Diploma in Veterinary Anaesthesia and Analgesia in 2006 and his European Diploma in Veterinary Pharmacology and Toxicology in 2014.

Ludovic's main research interests is pharmacology of analgesics, in particular NSAIDs and other drugs in species of veterinary interest (cats, dogs, , calves but also more exotic species such as emus or salamanders). He is developing research programs in pharmacology and pain management (acute and chronic), particularly in the area of pharmacokinetics and mathematical modeling (PK-PD).

Ludovic is promoting the use of pharmacometrics to help resolve clinical questions at the level of the invidual animal or for more global questions, as in the field of antimicrobial use and resistance. Ludovic is in the steering committee of , the veterinary section of the European Committee on Antimicrobial Susceptibility Testing (EUCAST).  Ludovic is the leader of the workpackage on Antimicrobials in the One Health Poultry Hub (). He is involved in European Consortiums, like the (Optimized dosing regimens for the combinations of sulfonamides and trimethoprim in veterinary medicine) with colleagues fron Toulouse, Uppsala and Ghent Universities and ANSES.

 

Ludovic collaborates in his research with colleagues from the 91°µÍø (, , , and others) and has established solid research or business relationships with external companies as ).

Ludovic is striving to expand the 91°µÍø analytical laboratory to support veterinary a therapeutic drug monitoring service and drug development schemes in collaboration with deltaDOT Ltd. A iohexol test is already avaialble to monitor glomerular filtration rate (GFR) in dogs and cats.

Current PhD students:

Ms Sophie Hedges: Quantifying the use and impact of antimicrobial drugs on chicken gut microbiome and the presence of resistance genes

 

Past PhD students:
Miss Hannah Kenward (co-supervisor: Jonathan Elliott and Karine Savary-Bataille, Zoetis):"Objectives measures of Nausea in the Dog". BBSRC CASE award.

Dr.  Sandra Sanchis Mora (co-supervisor Siobhan Abeyesinghe, Holger Volk and Transpharmation Ltd): "Multidisciplinary approach for improving diagnosis and treatment of spontaneous canine neuropathic pain". Click on the link below for further details:

Dr. Andrew Mead (co-supervison Richard Stabler LSHTM, Pascal Richez): PK PD informed clinical breakpoint determination for colistin in chicken to limit emergence of resistance and improve One Health antimicrobial sustainability

Dr. Stefano Azzariti (co-supervision Ross Bond): Bridging the preclinical/clinical gap for optimisation of efficacy and avoidance of resistance for fluoroquinolones, application to canine pyoderma

 

Research publications: latest

 

Selected publications below


Pelligand L, Guillot E, Geneteau A, Guyonnet J, Magnier R, Elliott J, Peyrou M, Jacobs M.
Front Vet Sci. 2020 Apr 28;7:151. doi: 10.3389/fvets.2020.00151.

. Pelligand L., Lees P., Sidhu P.K., Toutain P-L. Front. Microbiol., 11 June 2019 |

. Toutain P.-L., Sidhu P.K., Lees P., Rassouli A., Pelligand L.  Front. Microbiol., 12 June 2019 |

. Cuff A.R., Daley M.A., Michel K.B., Allen V.R., Lamas L.P., Adami C., Monticelli P., Pelligand L., Hutchinson J.R. J Morphol. 2019 May;280(5):666-680. doi: 10.1002/jmor.20973. Epub 2019 Mar 8.

: study protocol. Berk B.A., Packer R.M.A., Law T.H., Wessmann A., Bathen-Nöthen A., Jokinen T.S., Knebel A., Tipold A., Pelligand L., Volk H.A., BMC Vet Res. 2019 May 30;15(1):181. doi: 10.1186/s12917-019-1915-8.

Gozalo-Marcilla M., Luna S. P. L., Moreira da Silva R. , Crosignani N. , Lopes N. P., , Pelligand L., Taylor P. M.,  Equine Vet J. 2019 Jul;51(4):530-536. doi: 10.1111/evj.13054. Epub 2018 Dec 18.

. Gozalo-Marcilla M., Luna S. P. L., Moreira da Silva R. , Crosignani N. , Lopes N. P., Taylor P. M., Pelligand L. . Equine Vet J. 2019 Jul;51(4):517-529.

. Drozdzynska MJ, Chang YM, Stanzani G, Pelligand L. Vet Anaesth Analg. 2017 Jun 17

. Kenward H, Elliott J, Lee T, Pelligand L. BMC Vet Res. 2017 Aug 16;13(1):244.

. Sanchis-Mora S, Chang YM, Abeyesinghe S, Fisher A, Volk HA, Pelligand L. Vet Anaesth Analg. 2017 May;44(3):600-614

 Doodnaught GM, Monteiro BP, Benito J, Edge D, Beaudry F, Pelligand L, Steagall P. PLoS One. 2017 Apr 26;12(4):e0176443. doi: 10.1371/journal.pone.0176443. eCollection 2017

 Pelligand L, Soubret A, King JN, Elliott J, Mochel JP. CPT Pharmacometrics Syst Pharmacol. 2016 Oct 22.

 Toutain PL, Ferran AA, Bousquet-Melou A, Pelligand L, Lees P. Front Microbiol. 2016 Aug 3;7:1196.

 Pelligand L, Suemanotham N, King JN, Seewald W, Syme H, Smith K, Lees P, Elliott J. BMC Vet Res. 2015 Dec 3;11:296

 Cortellini S, Pelligand L, Syme H, Chang YM, Adamantos S. J Vet Intern Med. 2015 Nov-Dec;29(6):1595-602. doi: 10.1111/jvim.13638. Epub 2015 Sep 29.


Pelligand L., King J.N., Hormabazal V., Toutain P.L., Elliott J., Lees P:
JVPT, 2014 Mar 15. doi: 10.1111/jvp.12107.

 Kenward H, Pelligand L, Elliott J. Exp Brain Res. 2014 May 4. [Epub ahead of print]

 

 

 

 

 

 

Ludovic is teaching pharmacology to undergraduates for the BVSc2 courses.

 

 

Ludovic is joint-head of the 91°µÍø in the different hospitals (QMH, BSAH, Equine Referral Centre). He enjoys running the busy service, teaching students and anaesthesia residents and dealing with anaesthetic challenges.

 

International working group membership:

Member of the Therapeutic  Guidelines Group (TGG) of the World Small Animal Veterinary Association (WSAVA)

Invited member of the Comité Analyse et Maîtrise du Risque, Societe Francaise Anesthesie et Reanimation (SFAR)

Core founding member and the webmaster of the .   The objectives of this new society are explained in the following paper::    Mochel JP, Gabrielsson J, Collard W, Fink M, Gehring R, Laffont C, Liu Y, Martin-Jimenez T, Pelligand L, Steimer JL, Toutain PL, Whittem T, Riviere J.: Animal Health Modeling & Simulation Society: a new society promoting model-based approaches in veterinary pharmacology. J Vet Pharmacol Ther. 2013 May 29. doi: 10.1111/jvp.12060. [Epub ahead of print]. PMID: 23713757

 

  • Action project on Alternatives to Veterinary Antimicrobials (AVANT)

    Professor of Veterinary Bacteriology Luca Guardabassi is the coordinator of a large EU Innovation Action project on Alternatives to Veterinary Antimicrobials (AVANT) involving 8 industries, 5 universities and the Federation of Veterinarians of Europe.

    AVANT is a multi-actor inter-sectorial project aimed at developing alternatives to antimicrobials for the management of bacterial infections in pigs, especially diarrhoea during the weaning period, as the major indication for antimicrobial use in livestock in Europe. 

  • Optimized dosing regimens for the combinations of sulphonamides and trimethoprim in veterinary medicine (SulTAn)

    To fill the gaps related to the pharmacokinetics of Trimethoprim and Sulphonamides, and to the pharmacodynamics (PD) of their interaction on veterinary pathogens across multiple animal species.

    This project will focus on the combination of different S with TMP in veterinary medicine and will aim at determining the needed adjustments or revisions to optimize TMPS dosage regimens in domestic animal species.

  • PK/PD informed clinical breakpoint determination for colistin in chicken to limit emergence of resistance and improve One Health antimicrobial sustainability

    This project aims to evaluate the impact of colistin use on antimicrobial resistance and rationalise dosing through a combination of in vivo pharmacokinetic (PK) dose studies, in vitro pharmacodynamic (PD) and antimicrobial susceptibility testing, and advanced in silico PK/PD modelling.

    To maintain colistin as an essential antimicrobial for both human and veterinary use, recent and reliable data regarding the pharmacokinetics (PK) and pharmacodynamics (PD) at the clinical dose in poultry, and its impact on the potential selection of resistance is required to inform application and policy.

  • Quality of veterinary oral formulations of amoxicillin/clavulanic acid in World Small Animal Veterinary Association (WSAVA) member countries

    The 91°µÍø team is researching the deficits of amoxicillin/clavulanic acid (AMC) in tablet form, following more general concerns about substandard or falsified veterinary medicines being sold in some settings.

    The aim is to detect types and frequency of deficits in the quality of veterinary oral formulations of AMC and identify regional trends including differences between countries or between geographical areas within the same country.

    Lack of efficacy due to SF veterinary products may be life-threatening in the case of antimicrobials drugs or vaccines. Furthermore, SF antimicrobial products are likely to expose sick animals to sub therapeutic levels and contribute to treatment failure and antimicrobial resistance.

  • Temporal dynamic resistance of skin and gastrointestinal bacteria in canine pyoderma

    Temporal dynamic resistance of skin and gastrointestinal bacteria in canine pyoderma: Comparison between marbofloxacin and pradofloxacin in an investigator-blinded randomised interventional study. Pharmacokinetic data will be combined with MIC distribution together with the relationship between exposure and dynamic of bacterial kill modelled will be used to propose clinical breakpoints (highest MIC value considered “sensitive”) for fluoroquinolones in canine pyoderma.

  • UK Research and Innovation (UKRI) Global Challenges Research Fund (GCRF) One Health Poultry Hub

    With integrated streams of social, economic, biological, mathematical and policy-led research, we are co-producing detailed knowledge on the biological, structural and socio-economic factors that shape networks of chicken production and distribution. The 91°µÍø-led UKRI GCRF One Health Poultry Hub brings together leading laboratory, clinical, veterinary and social scientists, as well as skilled communications experts, programme support staff and external stakeholders.  

Top of page